Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Britain Courts Anthropic Amid US Defense Department Dispute 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
MENLO PARK, Calif., Oct. 13, 2016 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced that Dr. Samuel Barone, MD, Senior Vice President, Clinical Development will provide a brief corporate overview and data presentation today at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting in Chicago, IL.
The presentation is now available on the Company’s website at www.adverumbio.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet AMD, A1AT deficiency, and hereditary angioedema, among other diseases. We are leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverumbio.com
Contact for Adverum: Tricia Truehart Vice President The Trout Group LLC 646-378-2953 [email protected]
